LuCAB: A Phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Kostos, Louise [1 ,2 ]
Buteau, James P. [2 ,3 ]
Kong, Grace [2 ,3 ]
Opar, Petra [4 ]
Di Lulio, Juliana [4 ]
Fahey, Michael [4 ]
Fettke, Heidi [2 ,3 ]
Furic, Luc [3 ,5 ]
Hofman, Michael S. [2 ,3 ]
Azad, Arun [2 ,3 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Box Hill, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[5] Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs39
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [1] LuCAB: A PHASE I/II TRIAL EVALUATING CABAZITAXEL IN COMBINATION WITH (177Lu)Lu-PSMA-617 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Buteau, James
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 71 - 71
  • [2] LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Kostos, Louise Kathleen
    Buteau, James Patrick
    Kong, Grace
    Yeung, Theresa
    Di Iulio, Juliana
    Fahey, Michael T.
    Fettke, Heidi
    Furic, Luc
    Hofman, Michael S.
    Azad, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment
    Todenhoefer, Tilman
    AKTUELLE UROLOGIE, 2023, 54 (04)
  • [4] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [5] [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
    Hofman, Michael S.
    Emmett, Louise
    Sandhu, Shahneen
    Iravani, Amir
    Joshua, Anthony M.
    Goh, Jeffrey C.
    Pattison, David A.
    Tan, Thean Hsiang
    Kirkwood, Ian D.
    Ng, Siobhan
    Francis, Roslyn J.
    Gedye, Craig
    Rutherford, Natalie K.
    Weickhardt, Andrew
    Scott, Andrew M.
    Lee, Sze-Ting
    Kwan, Edmond M.
    Azad, Arun A.
    Ramdave, Shakher
    Redfern, Andrew D.
    Macdonald, William
    Guminski, Alex
    Hsiao, Edward
    Chua, Wei
    Lin, Peter
    Zhang, Alison Y.
    McJannett, Margaret M.
    Stockler, Martin R.
    Violet, John A.
    Williams, Scott G.
    Martin, Andrew J.
    Davis, Ian D.
    LANCET, 2021, 397 (10276): : 797 - 804
  • [6] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [7] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
  • [8] Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
    Herrmann, Ken
    Sartor, Oliver
    Castellano, Daniel
    de Bono, Johann
    Shore, Neal
    Chi, Kim
    Crosby, Mike
    Piulats, Josep
    Flechon, Aude
    Wei, Xiao
    Mahammedi, Hakim
    Roubaud, Guilhem
    Studentova, Hana
    Ghebremariam, Samson
    Kpamegan, Euloge
    Kreisl, Teri
    Delgoshaie, Neda
    Lehnhoff, Katja
    Morris, Michael
    Fizazi, Karim
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [9] Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
    Sartor, O.
    Gauna, D. E. Castellano
    Herrmann, K.
    de Bono, J. S.
    Shore, N. D.
    Chi, K. N. N.
    Crosby, M.
    Rodriguez, J. M. Piulats
    Flechon, A.
    Wei, X. X.
    Mahammedi, H.
    Roubaud, G.
    Ova, H.
    Ghebremariam, S.
    Kpamegan, E.
    Kreisl, T. N.
    Delgoshaie, N.
    Lehnhoff, K.
    Morris, M. J.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1324 - S1325
  • [10] Re: [177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial
    Adeleke, Sola
    Haroon, Athar
    Kasivisvanathan, Veeru
    EUROPEAN UROLOGY, 2021, 80 (01) : 118 - 119
12345